[Ankylosing spondylitis].
A FREQUENT AFFECTION: Ankylosing spondylitis is a chronic inflammatory rheumatism usually affecting young adults and characterized by an inflammatory enthesiopathy progressing towards ossification and ankylosis. It is ranked in second position of chronic inflammatory rheumatism, after rheumatoid arthritis. IMPROVING ITS EVOLUTION: Early diagnosis and adapted therapy would contribute in improving its prognosis and avoid the evolution to severe forms of the disease.


RESULTS
The recent advances in this disease are the enhanced knowledge of its physiopathology and the development of efficient drugs (anti-TNFalpha).
El Maghraoui
Abdellah
A
Cenrre de rheumatologie et rééducation fonctionnelle, Hôpital militaire d'instruction Mohammed V, Rabat, Morocco. abdellahe@menara.ma
D020083:Acquired Hyperostosis Syndrome / Q000175:diagnosis; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D016918:Arthritis, Reactive / Q000175:diagnosis; D001528:Behcet Syndrome / Q000175:diagnosis; D003937:Diagnosis, Differential; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008168:Lung / Q000000981:diagnostic imaging; D008727:Methotrexate / Q000627:therapeutic use; D000077268:Pamidronate; D025241:Spondylarthritis / Q000175:diagnosis; D013167:Spondylitis, Ankylosing / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D012460:Sulfasalazine / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D004164:Diphosphonates; D007166:Immunosuppressive Agents; D012460:Sulfasalazine; D013792:Thalidomide; D000077268:Pamidronate; D008727:Methotrexate